Inhibition of angiotensin-converting enzyme is the most studied mechanism for food-derived peptides, and it is also the clearest illustration of the gap between assay and outcome.
Key Takeaways
- Angiotensin-converting enzyme converts angiotensin I to the vasoconstrictor angiotensin II and degrades bradykinin.
- An inhibitor must survive digestion and reach vascular endothelium intact.
- Check whether the peptide was measured in plasma after oral administration and whether a controlled human endpoint was reported.
The mechanism
Angiotensin-converting enzyme converts angiotensin I to the vasoconstrictor angiotensin II and degrades bradykinin. Peptides that inhibit the enzyme in vitro can therefore plausibly influence blood pressure, which is why the assay became the field’s standard screen.
Structural preferences
Potent inhibitors frequently carry hydrophobic or aromatic residues at the C-terminus, and proline content is common. These features are useful for design but are weak predictors, since potency depends on the specific sequence context.
For related mechanism work, see plant-derived bioactive peptides.
The bioavailability objection
An inhibitor must survive digestion and reach vascular endothelium intact. Many characterised peptides are cleaved by gastrointestinal proteases, which is the principal reason that in vitro potency frequently fails to translate.
Where human data exist
Certain milk-derived tripeptides and some fish-derived sequences have controlled human blood-pressure data, generally showing modest effects. This is the strongest evidence available for any food peptide class and is still far from conclusive.
How to assess a claim
Check whether the peptide was measured in plasma after oral administration and whether a controlled human endpoint was reported. Without both, the claim describes enzyme chemistry rather than a physiological effect.
Experimental Conditions and Practical Setup
Inhibition is measured against a defined enzyme activity with the peptide concentration reported in molar terms, and the result is only meaningful alongside a stability arm in simulated gastrointestinal fluid. Many characterised inhibitors lose activity in that fluid, which explains the frequent failure to reproduce potency in vivo.
From assay to outcome: the filters a peptide must pass
| Filter | Question | Where most fail |
|---|---|---|
| Enzyme inhibition | Does it inhibit the target? | Many pass |
| Digestive stability | Does it survive proteases? | Many fail here |
| Absorption | Does intact peptide reach plasma? | Most fail here |
| Controlled human endpoint | Does blood pressure change? | Very few reach here |
Practical Notes for the Bench
- Require plasma measurement of the intact peptide after oral dosing.
- Treat C-terminal hydrophobicity as a design hint, not a potency predictor.
- Expect modest effect sizes even where human data exist.
Frequently Asked Questions
Does ACE inhibition in vitro lower blood pressure?
Not necessarily. The peptide must survive digestion and reach the endothelium intact, which many characterised sequences do not.
Which peptides have human evidence?
Certain milk-derived tripeptides and some marine sequences, generally showing modest blood-pressure effects in controlled trials.
What structural features help?
Hydrophobic or aromatic C-terminal residues and proline content are common among potent inhibitors.
Why do potent in vitro inhibitors often do nothing in vivo?
Because they are cleaved by gastrointestinal proteases before they can be absorbed, and because the concentrations used in assays are far above achievable plasma levels.
Related Reading
- plant-derived bioactive peptides
- food-derived bioactive peptides
- exorphin opioid peptides
- AOD-9604 peptide
- LL-37 antimicrobial peptide
References & Further Reading
- Li J et al. A novel ACE inhibitory peptide from Douchi hydrolysate: Stability, inhibition mechanism, and antihypertensive potential in spontaneously hypertensive rats. Food Chem. 2024. PubMed 39106751
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Dr. Aiko Tanaka, Bioactive Peptides & Dermatological Research.